Drug intelligence / Profile preview

clonazepam + methylprednisolone + oxcarbazepine + valproic acid

Development stage
Unknown
Lead developer
Roche
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular, Rectal, Intrathecal, Topical, Sublingual
01

Overview

This is a combination of four pharmaceutical drugs—clonazepam, methylprednisolone, oxcarbazepine, and valproic acid. Each component has a distinct mechanism of action and therapeutic use: - **Clonazepam** is a long-acting benzodiazepine that enhances gamma-aminobutyric acid (GABA) receptor responses in the central nervous system. It is primarily used to treat various seizure disorders and panic disorder[2]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts by binding to the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses[4][6][8]. - **Oxcarbazepine** is an anticonvulsant that stabilizes hyperexcited neural membranes by blocking voltage-sensitive sodium channels in the brain. It is mainly used for epilepsy management[7][10]. - **Valproic acid** (not detailed in search results but widely known) increases brain levels of GABA by inhibiting its degradation or enhancing its synthesis; it also blocks voltage-gated sodium channels and T-type calcium channels. It’s used for epilepsy, bipolar disorder, and migraine prophylaxis. There are no known fixed-dose combination products containing all four agents together; this listing represents their concurrent use rather than a marketed co-formulation.

02

Targets

NaV (Voltage-gated sodium channels)BZD site (GABA-A receptor benzodiazepine site)GR (Glucocorticoid receptor)CaV3 (Caveolin-3)ABAT (4-aminobutyrate aminotransferase)

Beyond the preview

Go deeper on clonazepam + methylprednisolone + oxcarbazepine + valproic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clonazepam + methylprednisolone + oxcarbazepine + valproic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call